Charles M Baum
CIK 1579824 · Founder, President, and CEO · last filed 2026-06-22
Charles M Baum is a Founder, President, and CEO who has filed 72 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing, for ACRV, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$47.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $16.1K across reported positions. 11 SEC filings were submitted jointly with ARRAY BIOPHARMA INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACRV | Director | 9,366 | $1.72 | $16.1K | $0 | 5 | 2026-06-22 |
| PMVP | Director | — | $1.13 | — | $0 | 7 | 2026-06-05 |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 4 | 2025-01-08 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Founder, President, and CEO | 114,482 | $58.70 | $6.72M | -$47.82M | 42 | 2024-01-23 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 0 | — | — | $0 | 4 | 2020-10-23 |
Recent Filings
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | ACRV | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | ACRV | Grant (A) | +9,366 | $0 | EDGAR |
| 2025-06-17 | ACRV | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −78,600 | $0 | EDGAR |
| 2024-06-24 | ACRV | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +19,650 | $0 | EDGAR |
| 2024-06-10 | PMVP | Grant (A) | — | $0 | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −237,871 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.